Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxcyte, Inc. (Nasdaq: PCVX) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage vaccine innovation company developing broad-spectrum conjugate and novel protein vaccines against bacterial diseases, Vaxcyte uses its SEC reports to communicate financial results, material agreements and key milestones for its pneumococcal conjugate vaccine (PCV) franchise and broader pipeline.
Investors can review Form 8-K current reports in which Vaxcyte furnishes press releases on quarterly financial results, clinical and regulatory updates, and significant contracts. For example, recent 8-K filings reference earnings announcements and a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific, under which Patheon will formulate, fill, package, label, test, manufacture and supply drug product for Vaxcyte at a facility in Greenville, North Carolina. These filings outline key commercial supply arrangements, binding minimum order commitments, term length and termination provisions.
In addition to 8-Ks, users can expect to find Vaxcyte’s periodic reports such as Form 10-Q and Form 10-K (when available), which typically include detailed discussions of the company’s PCV programs (VAX-31, VAX-24 and VAX-XL), early-stage candidates like VAX-A1 and VAX-GI, use of the XpressCF cell-free protein synthesis platform, risk factors and liquidity information. These documents help explain how Vaxcyte is prioritizing resources for its PCV franchise, its capital position and its manufacturing investments.
Stock Titan’s interface is designed to surface new Vaxcyte filings in near real time as they appear on EDGAR and to pair them with AI-generated summaries that highlight the sections most relevant to shareholders, such as clinical program updates, material agreements, and changes in strategy. Users can also look for Form 4 and related ownership filings to monitor insider transactions when they are reported. Together, these filings offer a structured view of how Vaxcyte is advancing its pneumococcal and bacterial vaccine programs from both a scientific and corporate perspective.
Andrew Guggenhime, listed as President and CFO of Vaxcyte, Inc. (PCVX) and a director, reported multiple dispositions of common stock tied to the vesting of restricted stock units (RSUs). On 09/02/2025 he surrendered 1,270, 2,381, and 1,429 shares to the issuer to cover tax withholding at a price of $31.56 per share. After those transactions his reported beneficial ownership in the class was 131,009, 128,628, and 127,199 shares on the separate reported lines. The filing notes that the total includes 329 shares acquired under the company Employee Stock Purchase Plan on May 16, 2025. The transactions appear to be routine tax-withholding actions related to RSU vesting.
Grant Pickering, who is listed as Vaxcyte, Inc.'s Chief Executive Officer and a director, reported transactions dated 09/02/2025 on Form 4. The filing shows three dispositions of Common Stock executed to satisfy tax withholding upon RSU vesting: 2,857 shares, 4,563 shares and 3,420 shares, each at a price of $31.56. Following those transactions the reported amounts beneficially owned on reported lines are 516,247, 511,684 and 508,264 shares respectively. The filing also reports 136,215 shares held indirectly in a trust for the reporting person’s son and 136,215 shares held indirectly in a trust for the reporting person’s daughter. The report notes 329 shares were acquired under the company ESPP on May 16, 2025. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Vaxcyte, Inc. (PCVX) Form 4: Elvia Cowan, SVP Finance, reported equity awards and purchases. On 08/29/2025 she was granted 2,810 restricted stock units (RSUs) that convert to common shares at vesting and a stock option covering 9,743 shares with an exercise price of $30.79 that vests monthly beginning 09/29/2025 and expires 08/29/2035. Following the reported RSU grant the filing shows she beneficially owns 27,205 shares, which includes 289 shares acquired under the Employee Stock Purchase Plan on 05/16/2025. All reported holdings are direct.
Janus Henderson Group plc filed a Schedule 13G/A reporting a sizable stake in Vaxcyte, Inc. The filing discloses an aggregate beneficial ownership reported as 14,691,344 shares (11.4% of the class). The document also states that an indirect subsidiary, JHIUS, may be deemed to beneficially own 14,554,724 shares (11.3% of the class), and that shared voting and shared dispositive power apply to those subsidiary-held shares.
The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and it attaches a power of attorney authorizing two officers to make future ownership filings on the company’s behalf.
Q2 2025 highlights from Vaxcyte, Inc. (PCVX) 10-Q. The company reported consolidated total assets of $3,305,363 and a six-month net loss of $307,291 (YTD), including a Q2 net loss of $166,573. Cash and cash equivalents declined to $306,744 at June 30, 2025 from $387,878 at December 31, 2024. Short-term and long-term investments totaled $2,519,774 (fair value).
Operating results and cash flow: R&D expense rose to $194,179 in Q2 2025 (Q2 2024: $131,507) and G&A to $32,040 (Q2 2024: $21,474), driving total operating expenses of $226,219 for the quarter. Net loss per share was $(1.22) for Q2 and $(2.26) for the six months. Net cash used in operating activities was $287,440 for the six months.
- Shares outstanding: 129,816,472 at June 30, 2025.
- Manufacturing buildout: $196.3M capital expenditures (company-owned) and $94.3M facility buildout expenditures owned/controlled by Lonza (including CHF27M repurposing fee).
- Commitments: $484,543K non-cancelable purchase commitments to manufacturing partners; lease liabilities total $85,845K (discounted).